| UHC UMR Medical and Drug | Infliximab (Avsola®, Inflectra®, Remicade®, & Renflexis®) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC UMR Medical and Drug | Intravenous Iron Replacement Therapy (Feraheme®, Injectafer®, & Monoferric®) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Infliximab (Avsola®, Inflectra®, Remicade®, & Renflexis®) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Intravenous Iron Replacement Therapy (Feraheme®, Injectafer®, & Monoferric®) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Ablative Treatment for Spinal Pain – Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Breast Imaging for Screening and Diagnosing Cancer – Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Cimzia® (Certolizumab Pegol) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Computer-Assisted Surgical Navigation for Musculoskeletal Procedures – Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Deep Brain and Cortical Stimulation – Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Commercial Medical & Drug | Durable Medical Equipment, Orthotics, Medical Supplies, and Repairs/Replacements – Commercial and Individual Exchange Medical Policy | 2026-02-01 |